BiotechTube

SAR446268

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myotonic Dystrophy

Conditions

Myotonic Dystrophy

Trial Timeline

Jul 23, 2025 → Feb 28, 2029

NCT ID
NCT06844214

About SAR446268

SAR446268 is a phase 1/2 stage product being developed by Sanofi for Myotonic Dystrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06844214. Target conditions include Myotonic Dystrophy.

What happened to similar drugs?

0 of 2 similar drugs in Myotonic Dystrophy were approved

Approved (0) Terminated (0) Active (2)
🔄Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
🔄DYNE-101 + PlaceboDyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06844214Phase 1/2Recruiting

Competing Products

16 competing products in Myotonic Dystrophy

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
TideglusibAMO PharmaPhase 2
25
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
VX-670Vertex PharmaceuticalsPhase 2
42
VX-670 + PlaceboVertex PharmaceuticalsPhase 1/2
39
rhIGF-I/rhIGFBP-3 + placeboInsmedPhase 2
32
IONIS-DMPKRx + PlaceboIonis PharmaceuticalsPhase 1/2
29
Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
44
ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) InjectionArrowhead PharmaceuticalsPhase 1/2
36
DYNE-101 + PlaceboDyne TherapeuticsPhase 3
41
DYNE-101 + PlaceboDyne TherapeuticsPhase 1/2
33
Pitolisant Oral Tablet + Placebo oral tabletHarmony BiosciencesPhase 2
29
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1 for infusionPepGenPhase 1
19